The usage of nanotechnology in the detection and treatment of cancer

Cancer remains a critical health challenge on a global level. Existing diagnostic and treatment methods have serious limitations which contribute to rising incidence and mortality, this study explores the usage of nanotechnology to overcome these limitations by enabling earlier tumor detection and making treatments more precisely targeted. Conventional imaging techniques often fail to spot tumors in early stages or differentiate benign growths from malignant ones, while also typically relying on ionizing radiation, which can damage healthy tissues. Similarly, standard cancer therapies often cause severe side effects due to the lack of specificity and inability of eliminating tumors without harming normal cells. This study examines the usage of emerging nanotechnology-enabled tools, including silicon nanowire biosensors, which exhibit exceptionally high sensitivity and could allow for tumor detection at much earlier stages. Beyond diagnostics, nanotechnology can also enhance therapy: nanocarrier systems (for example, liposomes) can deliver anticancer drugs directly to tumor sites, thereby reducing exposure of healthy tissues. Similarly, stimuli-responsive systems such as ultrasound-triggered drug release could further improve treatment precision and effectiveness. However, like any emerging approach, challenges remain: sensor devices may suffer from background noise, some nanomaterials could pose toxicity risks, and high development costs currently limit widespread adoption. This work is based on an extensive review of peer-reviewed literature and expert consultation, aimed at evaluating the feasibility and potential impact of nanotechnology in oncology. The findings suggest that nanotechnology holds significant promise for cancer care. At the same time, the results underscore the need for continued research to overcome existing limitations.